Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.00 Consensus Target Price from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $35.00.

A number of analysts have recently commented on the stock. Rodman & Renshaw began coverage on shares of Alto Neuroscience in a report on Friday, June 21st. They set a “buy” rating and a $43.00 target price on the stock. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th.

Alto Neuroscience Trading Up 6.0 %

NYSE:ANRO opened at $9.52 on Friday. The firm has a fifty day moving average of $11.86. Alto Neuroscience has a twelve month low of $7.91 and a twelve month high of $24.00. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.07. On average, analysts expect that Alto Neuroscience will post -2.93 EPS for the current year.

Insider Buying and Selling at Alto Neuroscience

In other news, insider Adam Savitz purchased 12,069 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was acquired at an average cost of $12.60 per share, for a total transaction of $152,069.40. Following the purchase, the insider now directly owns 36,920 shares in the company, valued at approximately $465,192. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently made changes to their positions in the company. University of Texas Texas AM Investment Managment Co. bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $340,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $7,039,000. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $8,233,000. Price T Rowe Associates Inc. MD bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $9,788,000. Finally, AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $4,592,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.